Skip Navigation LinksHome > October 2009 - Volume 31 - Issue 10 > Low Dose Vincristine-induced Severe Polyneuropathy in a Hodg...
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e3181b530ad
Clinical and Laboratory Observations

Low Dose Vincristine-induced Severe Polyneuropathy in a Hodgkin Lymphoma Patient: A Case Report (Vincristine-induced Severe Polyneuropathy)

Cil, Timucin MD*; Altintas, Abdullah MD; Tamam, Yusuf MD; Battaloğlu, Esra PhD§; Isikdogan, Abdurrahman MD*

Collapse Box

Abstract

Chemotherapeutic drugs are the most common toxic agents for peripheral nerves. Vincristine is a vinca alkaloid drug that is used for the treatment of several malignancies in combination with other chemotherapeutic agents. Treatment with intravenous (IV) vincristine at doses above 5 mg leads to a dose-dependent neuropathy with sensory symptoms but higher cumulative doses at around 30 to 50 mg are needed for the development of motor symptoms. The standard maximum adult IV vincristine dose is 2 mg IV per dose given at weekly intervals. However, administration of a single 2-mg dose IV vincristine may rarely result in the development of peripheral neuropathy. Few case reports have been presented on vincristine-associated severe paralysis in patients with preexisting hereditary neuropathy like Charcot-Marie Tooth (CMT) disease, who received doses even lower than 2 mg. Herein, we reported a Hodgkin lymphoma patient who developed severe polyneuropathy after receiving 2 mg vincristine treatment and was subsequently found to carry the CMT1A duplication responsible for CMT disease.

© 2009 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/JPHOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.